BioPharma Dive November 25, 2024
Ben Fidler

While Biohaven’s medicine may no longer be competitive in spinal muscular atrophy, the company saw enough potential for it as a weight loss treatment to plan a fast launch of a Phase 2 study.

Dive Brief:

  • An experimental, muscle-preserving drug from Biohaven fell short of its goal in a Phase 3 study of people with spinal muscular atrophy, but showed enough promise in its effects on body composition that the company plans to advance it as a treatment for obesity.
  • A regimen of Biohaven’s drug, taldefgrobep alfa, and a standard SMA therapy didn’t significantly improve motor function after 48 weeks compared to treatment with a typical SMA medicine and placebo. Biohaven didn’t provide full study data in a Monday...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, Pharma / Biotech, Trends
Related Articles:
Gene Therapy for Cardiomyopathies Presents Promising Alternative to Current Treatment
STAT+: 3 trends to watch in biotech in 2025
The GLP-1 dilemma persists into 2025
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions

Share This Article